Company intelligence

Setara Biosciences

As of October 30, 2026, Setara Biosciences has raised at least $90M in equity across 1 sourced funding round.

BiotechSee connections →

Setara Biosciences at a glance

As of
Equity raised
$90M[1]
Across 1 sourced roundDerived
  1. [1] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), October 30, 2026
Ranked on: #33 Largest Series A Rounds of 2026 (Ranked)

Is something wrong on this page?

Recent changes

  1. Oct 30, 2026Raised $90M Series A BioPharma Dive
  2. Oct 30, 2026New investor: EcoR1 Capital BioPharma Dive
  3. Oct 30, 2026New investor: Canaan Partners BioPharma Dive
  4. Oct 30, 2026New investor: Regeneron Ventures BioPharma Dive

Funding history

1 equity event · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Oct 30, 2026Series A$90M—
—
WithCanaan PartnersunverifiedEcoR1 CapitalunverifiedRegeneron VenturesunverifiedDeerfield ManagementDroia VenturesEuclidean CapitalJazz Pharmaceuticals
BioPharma Dive

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Investors

Canaan PartnersEcoR1 CapitalRegeneron Ventures

Latest Pulse

  1. Setara Raises $90M, Inherits Actio's Rare-Disease PipelineSetara Biosciences launched with $90 million in Series A funding to carry forward Actio Biosciences' rare-disease drug pipeline after Jazz Pharmaceuticals' $820 million acquisition of Actio.→

Coverage Timeline

newest first
  1. Oct 30, 2026FUNDINGSetara Raises $90M, Inherits Actio's Rare-Disease Pipeline$90M Series A→

All Coverage

FUNDING
Setara Raises $90M, Inherits Actio's Rare-Disease Pipeline
FUNDING$90M Series A

Setara Raises $90M, Inherits Actio's Rare-Disease Pipeline

Setara Biosciences launched with $90 million in Series A funding to carry forward Actio Biosciences' rare-disease drug pipeline after Jazz Pharmaceuticals' $820 million acquisition of Actio.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

Setara Biosciences FAQ

How much has Setara Biosciences raised?

Setara Biosciences has raised at least $90M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $90M Series A in October 2026, reported by BioPharma Dive. Debt financing, tender offers and secondary sales are not counted.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·